Sirius Genomics announced that it has elected its 2009 Board of Directors at its recent Annual General Meeting.
The six-member Board consists of: Dr. James McEwen (Chairman), Dr. Heiner Dreismann, Mr. Jim Heppell, Mr. Amos Michelson, Dr. Bradley Popovich and Mr. Patrick Terry.
"With the global expertise in molecular diagnostics, commercialization and personalized medicine experience that is prevalent on our Board, Sirius will remain on course to successfully bring our first companion diagnostic, intended to assess responsiveness to recombinant human activated Protein C, to market.
"Under this leadership, Sirius will be situated to become a worldwide participant in the growing field of companion diagnostics and personalized medicine," stated Dr. Popovich, President and CEO of Sirius Genomics.
Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine.
